Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
August 10, 2022 16:30 ET
|
Decibel Therapeutics, Inc.
- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy...
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
June 28, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a potential...
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
June 03, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
May 02, 2022 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
March 18, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - - Research...
Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 16:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline
February 09, 2022 18:00 ET
|
Decibel Therapeutics, Inc.
- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability...
Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
January 31, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 04, 2022 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...